

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

FITC anti-mouse CD3

RRID:AB_312660

Type: Antibody

Proper Citation

BioLegend Cat# 100203, RRID:AB_312660

Antibody Information

URL: http://antibodyregistry.org/AB_312660

Proper Citation: BioLegend Cat# 100203, RRID:AB_312660

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_312660

Vendor: BioLegend

Catalog Number: 100203

Alternative Catalog Numbers: 100204

Record Creation Time: 20250819T211059+0000

Record Last Update: 20250819T220738+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-mouse CD3.

No alerts have been found for FITC anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 94 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tong T, et al. (2026) Microbial metabolite FAD mobilizes adipocyte lipid remodeling to enhance cancer immunotherapy efficacy. *Cell metabolism*, 38(3), 565.

Liao F, et al. (2026) Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression. *Cancer research*, 86(8), 1968.

Yang Q, et al. (2026) MSH6 regulates cGAS activity in antiviral and antitumor signaling pathways by governing its cytosolic/nuclear distribution. *Cell reports*, 45(3), 117059.

Xu Y, et al. (2026) KCTD10 weakens m6A modification of IL-11 in a ubiquitin-dependent manner to repress tumour immune escape in lung adenocarcinoma. *British journal of pharmacology*, 183(16), 4778.

Ho YH, et al. (2026) Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer. *Cell*, 189(14), 4276.

Ding T, et al. (2026) Dexamethasone ameliorates dermatologic adverse effects of PEGylated liposomal doxorubicin. *Journal of controlled release : official journal of the Controlled Release Society*, 396, 115057.

Kourtesakis A, et al. (2026) A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct. *Molecular therapy. Oncology*, 34(1), 201134.

Thorhallsdottir G, et al. (2026) Targeted TNF Potentiates the Activity of Bispecific T-cell Engagers in Solid Tumors by Turning Cold Tumors Hot. *Cancer immunology research*, 14(6), 919.

Liu Y, et al. (2026) Topical application of low-concentration IL-2 enhances Treg's function and plays anti-inflammatory roles in experimental dry eye disease. *The ocular surface*, 42, 1.

Qu C, et al. (2026) Targeted extracellular vesicle-photoimmunotherapy remodels stromal-immune microenvironment to boost chemo-immunotherapy in preclinical models. *Cell reports. Medicine*, 7(7), 102843.

Qian P, et al. (2026) Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis. *Immunity*, 59(7), 1964.

Savvateev I, et al. (2026) Toxoplasma gondii-induced region-specific disintegration in glutamatergic neurotransmission is linked to cognitive impairments in mice. *iScience*, 29(1), 114415.

Chen M, et al. (2026) Nano-granulated zoledronate sensitizes innate immune metabolism to enhance vaccine-induced and antitumor immunity. *Cell reports. Medicine*, 7(5), 102765.

Wang S, et al. (2026) ENPP1 buffers extracellular cGAMP in brown adipose tissue to limit insulin resistance. *bioRxiv : the preprint server for biology*.

Eissa IR, et al. (2026) The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. *iScience*, 29(7), 116500.

Imanishi I, et al. (2025) A basophil-fibroblast pro-inflammatory axis fuels type 2 skin inflammation. *Cell reports*, 44(8), 116114.

Zhang S, et al. (2025) p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma. *Cell reports*, 45(1), 116769.

Weller C, et al. (2025) Translation dysregulation in cancer as a source for targetable antigens. *Cancer cell*, 43(5), 823.

Allman A, et al. (2025) Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs. *Immunity*, 58(1), 143.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. *Cell reports*, 44(7), 115866.